| Authors: |
Farris M; Market Access & Health Economics, AstraZeneca, Macquarie Park, NSW, Australia., Christensen J; Respiratory and Immunology, AstraZeneca, Macquarie Park, NSW, Australia., Golder V; Associate Professor & Director of Undergraduate Medical Education, School of Clinical Sciences, Monash University, Melbourne, VIC, Australia., Kemp D; Health Economist, Dante Kemp Consulting Services, Merewether Heights, NSW, Australia; The South West Sydney Clinical Campuses, School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney., Morand EF; Centre for Inflammatory Diseases, School of Clinical Sciences, Sub-Faculty of Clinical and Molecular Medicine, Monash University, Melbourne, VIC, Australia., Nikpour M; Faculty of Medicine and Health, School of Public Health, University of Sydney, Sydney, NSW, Australia; Royal Prince Alfred Hospital Sydney, New South Wales, Australia., Kandane-Rathnayake R; Centre for Inflammatory Diseases, School of Clinical Sciences, Sub-Faculty of Clinical and Molecular Medicine, Monash University, Melbourne, VIC, Australia., Sierakowski W; THEMA Consulting Pty Ltd, Milsons Point, NSW, Australia., Tilden D; THEMA Consulting Pty Ltd, Milsons Point, NSW, Australia., Lee KW; GMAP, AstraZeneca, Cambridge, United Kingdom. Electronic address: kaiwai.lee@astrazeneca.com. |
